148 related articles for article (PubMed ID: 31377434)
1. How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
Santini D; Galvano A; Pantano F; Incorvaia L; Rizzo S; Vincenzi B; Castellana L; Giuliana G; Guadagni F; Toia F; Tonini G; Russo A; Badalamenti G; Bazan V
Crit Rev Oncol Hematol; 2019 Oct; 142():68-75. PubMed ID: 31377434
[TBL] [Abstract][Full Text] [Related]
2. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
3. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
4. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
6. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Jiang L; Cui X; Ma H; Tang X
J Orthop Surg Res; 2021 Jun; 16(1):400. PubMed ID: 34158101
[TBL] [Abstract][Full Text] [Related]
7. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Awan AA; Hutton B; Hilton J; Mazzarello S; Van Poznak C; Vandermeer L; Bota B; Stober C; Sienkiewicz M; Fergusson D; Shorr R; Clemons M
Breast Cancer Res Treat; 2019 Aug; 176(3):507-517. PubMed ID: 31079283
[TBL] [Abstract][Full Text] [Related]
8. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
9. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
Lipton A
Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
15. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
Cameron D
Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
[TBL] [Abstract][Full Text] [Related]
16. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Saad F; Chen YM; Gleason DM; Chin J
Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Lacerna L; Hohneker J
Semin Oncol; 2003 Oct; 30(5 Suppl 16):150-60. PubMed ID: 14613036
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
20. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
